Famitinib

[Olga]

New TKI that is showing the activity in soft tissue sarcomas and in ASPS specifically - multitargeting tyrosine kinase inhibitor that acts against vascular endothelial growth factor receptor-2, platelet-derived growth factor receptor, stem cell factor receptor (c-kit), FMS-like tyrosine kinase-3 receptor and protooncogene tyrosine kinase receptor
http://www.ncbi.nlm.nih.gov/pubmed/24043137
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Eight partial responses were determined, including 6 cases of renal cell carcinoma, 1 case of gastrointestinal stromal tumor (GIST) and 1 case of alveolar soft part sarcoma.
So far it is only tested in Beijing, China.